Evidence map›Paper›PMID 31591002›Full record

GuidelineAtherosclerosis2019

2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.

Authors/Task Force Members, ESC Committee for Practice Guidelines (CPG), ESC National Cardiac Societies

Erratum issued 3 registry-linked trialsAbstract readPractice GuidelineReview
PubMed Publisher
In one paragraph

Guideline in Atherosclerosis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 3 registered trials, which are not on this map. Cited by 526 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
526citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05613400 phase4unknown statusstarted 2022, after this paper: background citation

The Effect of Simvastatin on Bone Density in Postmenopausal Women With Type 2 Diabetes: a Double-blind, Randomized Active-comparator (Ezetimibe) Controlled Clinical Trial

Ran2022Enrolled240Registered outcomes7Posted comparisons0ConditionsDiabetes Mellitus, Type 2ArmsEzetimibe 10mg, Simvastatin 10mg
PMID 28434032PMID 10720052PMID 15317608PMID 17530471PMID 30403505PMID 30674078PMID 31384961PMID 32385660PMID 33605046PMID 30615801PMID 11701680PMID 12713767other papers from this trial
Open the trial in the graph
NCT04894318 nacompletednot on this map

The Short Term Beneficıal Effects Of A Low-Fat And Low-Cholesterol Dietary Intervention On LDL Sub-Groups In Dyslipidemic Turkish Patients

TypeinterventionalSponsorTC Erciyes UniversityRan2017 to 2019Enrolled47ConditionsDyslipidemiasArmsLow-fat and low-cholesterol diet
NCT06248138 unknown statusnot on this mapstarted 2024, after this paper: background citation

Factors Related to the Progression of Non-target Coronary Lesions

TypeobservationalSponsorMei GaoRan2024 to 2024Enrolled1,111ConditionsCoronary Stenosis
3 · Its place in the literature

Who cites it

526 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Guideline
  7. Pooled it
  8. Pooled it
  9. PCSK-9-inhibitor therapy improves endothelial function in high-risk patients with cardiovascular disease.Clinical research in cardiology : official journal of the German Cardiac Society · 2026
    Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

466 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Authors/Task Force Members
ESC Committee for Practice Guidelines (CPG)
ESC National Cardiac Societies

Funding

Medical Research Council MC_U137686849Medical Research Council MC_UU_00017/4Medical Research Council MC_UU_12026/6
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAgedBiomarkersCardiovascular DiseasesConsensusDrug Therapy, CombinationDyslipidemiasFemaleHumansHypolipidemic AgentsLipidsMaleMiddle AgedRisk AssessmentRisk FactorsRisk Reduction BehaviorBiomarkersHypolipidemic AgentsLipidsApolipoprotein BCholesterol;DyslipidaemiasFamilial hypercholesterolaemiaGuidelinesHigh-density lipoproteinsLipoprotein(a)Lipoprotein remnantsLow-density lipoproteinsTotal cardiovascular riskTreatment (adherence)Treatment (drugs)Treatment (lifestyle)TriglyceridesVery low-density lipoproteins

Identifiers

PMID31591002

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.